$AQST

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly failing to disclose FDA deficiencies in Anaphylm NDA, causing 37% stock decline.

Aquestive Therapeutics faces securities fraud lawsuit after FDA rejected Anaphylm drug, contradicting management's prior "on track" statements; $AQST stock fell 37%.

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against Aquestive Therapeutics over alleged false statements regarding Anaphylm drug application.

Aquestive Therapeutics appoints Day Pitney partner Thomas Zalewski as Chief Legal Officer and Chief Compliance Officer, with Lori Braender transitioning to Corporate Secretary after eight years.

Portnoy Law Firm files class action against $AQST for allegedly misleading investors about Anaphylm FDA prospects. Stock plunged 37% after deficiency disclosure.

$AQST plummets 37% after FDA rejects Anaphylm application. Investors sue over alleged misleading statements about approval prospects.

Class action lawsuit filed against $AQST alleging misleading statements about FDA approval timeline for Anaphylm and concealed human factors risks.

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory and renewable energy credits. Deadline April 20, 2026.

Rosen Law Firm filed class action against Aquestive Therapeutics alleging false statements about product development and regulatory matters. Eligible investors should act before deadline.

Rosen Law Firm files securities class action against $AQST over alleged misleading statements regarding its Anaphylm drug application between June 2025 and January 2026.

Law firm Levi & Korsinsky files class action against Boston Scientific, citing misleading statements. Stock tumbled 17.6% after disappointing Q4 2025 earnings and weak 2026 guidance.

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.

Aquestive to present clinical trial data for Anaphylm, an investigational oral anaphylaxis treatment, at 2026 allergy conference, showing promising safety and efficacy results.

Aquestive Therapeutics' stock plunged 40% after FDA cited major deficiencies in its Anaphylm anaphylaxis treatment application. Shareholder lawsuit investigation underway over disclosure adequacy.